cardiovascular co-morbidities in patients with PsA
Study | Type of study | Comparison group | Subjects; total number (ascertainment procedures); gender distribution; age, years | Time period | Statistical analyses | Findings |
---|---|---|---|---|---|---|
Han18 | Cross-sectional study; patient source: PharMetrics Patient-Centric Database, USA | Four matched controls: sex, age, geographical region, previous length of time in plan | 3066 PsA patients (ICD-9);49.7±11.2 years | 2001–2 | Age and sex adjusted prevalences of comorbidities; the prevalence ratios were estimated by Cochran–Mantel–Haenszel method | Increased prevalence of:* ischaemic heart disease (7.3%); peripheral vascular disease (2.9%); congestive heart failure (1.9%); cerebrovascular disease (3.1%) |
Gladman17 | Prospective cohort | Canadian Community Health Survey | 648 PsA patients (inflammatory arthritis associated with psoriasis); 56% male; 43.5 years | 1978–2004 | Cross-sectional examination with age and gender matched groups; SPR were calculated; Cox relative risk regression analysis | Increased SPR:* angina (SPR 1.97); myocardial infarction (SPR 2.57) |
Jamnitski19 | Single-centre study | Comparison with 353 RA patients43 | 489 PsA patients aged between 50 and 75 years (according to Moll and Wright criteria) | 2010 | Logistic regression analysis | Cardiovascular disease defined as a history of myocardial infarction and/or stroke and/or transient ischaemic attack; prevalence of cardiovascular disease in PsA was 10% compared to 12% in RA; OR 0.78; 95% CI 0.51 to 1.20, p=0.26; also age and sex stratified OR were not different between RA and PsA |
Ahlehoff7 | Population-based study | General population of Denmark (n=4 003 265) | 607 PsA patients (ICD-8 and 10); age and gender distribution of PsA patients are lacking | 1997–2006 | RR and 95% CI; Poisson regression models; confounders: age, calendar year, concomitant medication use, comorbidity, socioeconomic data, gender | Increased cardiovascular risk in PsA patients; RR 1.79; 95% CI 1.31 to 2.45† |